[The following content is from AI]

Based on the effective growth of MA 4.98%, re-adjusting PE and stock price.

Core Base (Latest as of 2026/4/7)

• 2026 Official EPS Guidance: ≥$17.75

• 2027 EPS (Post-fee): $21.33 (Raymond James raised on 4/1)

• Historical Normal Forward PE: 17–22x (Average ≈20–22x)

• Current Stock Price: $281.36

Valuation Calculation (PE Range × 2027E EPS)

• Undervalued Zone (≤16x): $21.33×16=$341.28 (High safety margin)

• Fair Value Zone (17–22x):

◦ 17x: $21.33×17=$362.61

◦ 20x: $21.33×20=$426.6

◦ 22x: $21.33×22=$469.26

• Overvalued Zone (≥23x): $21.33×23=$490.59 (Valuation stretched, sentiment premium)

Key Revisions Compared to the Old Range

• Old Version (Based on 2026E $17.75): Fair Value Zone $301.75–$390

• New Version (Based on 2027E $21.33): Fair Value Zone $362–$469

• Change Logic: EPS revised up by ~$1.89, valuation center shifted up by $60+, 4.98% fee rate + Optum AI cost reduction significantly boosted profitability.

Institutional Validation

• Raymond James (4/1): Target Price $330 (22×$21.33)

• TipRanks Consensus: $366.47

• Conservative Anchor: TD Cowen's original $311 (already appears conservative)

Quick Summary

• ✅ Undervalued: ≤**$341** (Safe zone, PE≤16)

• ⚖️ Fair Value: $362～$469 (Normal price, PE17–22)

• ❌ Overvalued: ≥**$491** (A bit expensive, PE≥23)

$Unitedhealth(UNH.US)